People: Questcor Pharmaceuticals, Inc. (QCOR.O)

QCOR.O on Consolidated Issue listed on NASDAQ Global Market

4.57USD
9 Feb 2010
Price Change (% chg)

$0.14 (+3.16%)
Prev Close
$4.57
Open
--
Day's High
$4.58
Day's Low
$4.41
Volume
215,194
Avg. Vol
409,262
52-wk High
$7.82
52-wk Low
$3.10

view people for:

Summary

Name Age Since Current Position
Thompson, Virgil 69 2009 Chairman of the Board
Bailey, Don 63 2007 President, Chief Executive Officer, Director
Sawka, Gary 62 2008 Chief Financial Officer, Senior Vice President - Finance
Cartt, Stephen 47 2010 Executive Vice President & Chief Business Officer
Medeiros, David 57 2007 Senior Vice President - Pharmaceutical Operations
Halladay, Steven 61 2006 Senior Vice President - Clinical and Regulatory Affairs
Young, David 56 2009 Chief Scientific Officer
Zielonka, Jason 61 2010 Chief Medical Officer
Bradsher, Neal 44 2004 Director
Lapointe, Gregg 50 2009 Director
Farrell, Stephen 44 2007 Director
Silverman, Louis 51 2009 Director
» Insider Trading

Biographies

Name Description
Thompson, Virgil Virgil D. Thompson joined the Questcor Pharmaceuticals, Inc.’s Board of Directors in January 1996 and serves as Chairman of the Board. Mr. Thompson has served as the President, Chief Executive Officer and as a Director of Angstrom Pharmaceuticals, Inc. from November 2002 until July 2007, where he continues to serve as director. From September 2000 until August 2002, Mr. Thompson was President, Chief Executive Officer and a director of Chimeric Therapies, Inc. From May 1999 until September 2000, Mr. Thompson was President, Chief Operating Officer and a director of Bio-Technology General Corporation, a pharmaceutical company (now Savient Pharmaceuticals, Inc.). Mr. Thompson is also the Chairman of the Board of Directors of Aradigm Corporation and a director of Savient Pharmaceuticals, Inc. Mr. Thompson holds a B.S. degree in pharmacy from the Kansas University and a J.D. degree from The George Washington University Law School.
Bailey, Don Don M. Bailey has served as President and Chief Executive Officer, joined Board of Directors of Questcor Pharmaceuticals Inc in May 2006. Mr. Bailey was appointed interim President in May 2007. Mr. Bailey was appointed President and Chief Executive Officer of the Company in November 2007. Mr. Bailey is currently the non-executive Chairman of the Board of STAAR Surgical Company. STAAR Surgical Company is a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies. Mr. Bailey was the Chairman of the Board of Comarco, Inc. from 1998 until 2007 and was employed by Comarco, Inc., where he served as its Chief Executive Officer from 1991 to 2000. Mr. Bailey has been Chairman of the Board of STAAR since April 2005. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California, and an M.B.A. from Pepperdine University.
Sawka, Gary Gary M. Sawka has served as Senior Vice President, Finance and Chief Financial Officer, joined Questcor Pharmaceuticals Inc in September 2008. From February 2007 to April 2008, Mr. Sawka served as the Chief Financial Officer and Designated Responsible Individual of Tripath Technology, Inc., a former NASDAQ-listed fabless semiconductor company, during its Chapter 11 reorganization and its reverse merger. From August 2006 to February 2007, he served as a consulting Chief Financial Officer to Tripath Technology, Inc. From 2002 to 2006, Mr. Sawka worked as a financial consultant for several NASDAQ-listed companies. From 2000 to 2001, he served as Executive Vice President and Chief Financial Officer of ePlanning Securities, a national, representative-owned, independent FINRA Broker / Dealer. During the period from 1984 to 2002, Mr. Sawka served as Vice President and Chief Financial Officer of Tvia, Inc.(OTC: TVIA.PK), a fabless semiconductor company, PrimeSource Corporation, an international container leasing company specializing in high service leases, and Itel Containers International Corporation, at that time, the world’s largest international container leasing company. Since May 2007, Mr. Sawka has served on the Board of Directors of CAI International, Inc. (NYSE: CAP) an international container leasing and management company, where he is a member of the Audit and Compensation Committees and Chairs the Corporate Governance and Nominating Committee. Mr. Sawka has an M.B.A. from Harvard University Graduate School of Business Administration and a B.S. in Accounting from the University of Southern California.
Cartt, Stephen Stephen L. Cartt has been appointed as the Executive Vice President & Chief Business Officer of Questcor Pharmaceuticals, Inc. He served as the Executive Vice President, Corporate Development, joined Questcor Pharmaceuticals Inc in March 2005. Mr. Cartt was a private consultant from August 2002 until March 2005. From March 2000 through August 2002, Mr. Cartt was the Senior Director of Strategic Marketing for Elan Pharmaceuticals. Mr. Cartt holds a Bachelor of Science degree from the University of California at Davis in biochemistry, and an Master of Business Administration from Santa Clara University.
Medeiros, David David J. Medeiros has served as Senior Vice President, Pharmaceutical Operations, joined Questcor Pharmaceuticals Inc in June 2003 as Vice President, Manufacturing. Prior to joining the Company, Mr. Medeiros served as Senior Director, Manufacturing at Titan Pharmaceuticals, Inc. from November 2000 to June 2003. Mr. Medeiros holds a B.S. degree in chemical engineering from San Jose State University, a Master’s degree in chemical engineering from University of California, Berkeley and an M.B.A. from the University of California at Berkeley.
Halladay, Steven Steven C. Halladay has served as Senior Vice President, Clinical and Regulatory Affairs, joined Questcor Pharmaceuticals Inc in October 2006. Prior to joining the Company, Dr. Halladay served as Vice President, Clinical and Regulatory Affairs of Durect Corporation from September 2002 to October 2006. Prior to joining Durect, Dr. Halladay served as Senior Executive Vice President of Clingenix, Inc. from 2000 to 2002 and as President and Chief Executive Officer of its wholly-owned subsidiary, Research Services, Inc. from 1995 to 2001. Dr. Halladay holds a B.S. from Southern Utah University in zoology, an M.S. from the University of Arizona in toxicology and a doctorate of Philosophy from the University of Arizona Medical Center in clinical pharmacology.
Young, David Dr. David Young, Ph.D., has been appointed as Chief Scientific Officer of Questcor Pharmaceuticals, Inc. He joined the Questcor Pharmaceuticals, Inc.’s Board of Directors in September 2006. Dr. Young is currently President of AGI Therapeutics, Inc. Previously, Dr. Young was the Executive Vice President of the Strategic Drug Development Division of ICON plc, an international CRO, and founder and CEO of GloboMax LLC, a contract drug development firm purchased by ICON plc in 2003. Prior to forming GloboMax, Dr. Young was an Associate Professor at the School of Pharmacy, University of Maryland where he held a number of roles including Director of the Pharmacokinetics and Biopharmaceutics Lab and Managing Director of the University of Maryland-VA Clinical Research Unit. Dr. Young holds a Bachelor of Science degree in physiology from the University of California, Berkeley, an Master of Science degree in physics from the University of Wisconsin-Madison, a Pharm.D. from the University of Southern California and a Ph.D. in pharmaceutical sciences from the University of Southern California.
Zielonka, Jason Dr. Jason Zielonka, M.D. was appointed as the Chief Medical Officer of Questcor Pharmaceuticals, Inc effective February 16, 2010. Prior to joining Questcor, Dr. Zielonka was the Senior Medical Director for Trial Methodology at Ortho-McNeil Janssen, Johnson and Johnson's primary U.S. pharmaceuticals business. He also held senior positions in Clinical Research and Medical Affairs at Pfizer, DuPont Pharmaceuticals and Bristol-Myers Squibb, as well as several other pharmaceutical companies. Prior to joining the pharmaceutical industry, Dr. Zielonka was Chief of Nuclear Medicine Services at the Veterans' Administration Medical Center and Assistant Professor of Radiology at the Medical College of Wisconsin. Dr. Zielonka received his Bachelor of Science in Electrical Science and Engineering from the Massachusetts Institute of Technology, his M.D. from the Yale University School of Medicine and his Nuclear Medicine fellowship training at the Harvard Medical School.
Bradsher, Neal Neal C. Bradsher, CFA, joined the Questcor Pharmaceuticals, Inc.’s Board of Directors in March 2004. Mr. Bradsher served as Lead Director of the Company from May 2004 to October 2004. Since 2002, Mr. Bradsher has been President of Broadwood Capital, Inc., a private investment firm. Previously, he was a Managing Director at Whitehall Asset Management, Inc. from 1999 to 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a chartered financial analyst.
Lapointe, Gregg Mr. Gregg Lapointe has been appointed as Director of Questcor Pharmaceuticals, Inc. He had served as Director of Questcor Pharmaceuticals, Inc from July 6, 2005 to Sept. 2007. Mr. Lapointe joined Sigma-Tau in September 2001 as Vice President, Finance, became Chief Operating Officer in November 2003, and Chief Executive Officer in April 2008. Prior to joining Sigma-Tau, he served as Vice President of Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.). Previously, Mr. Lapointe spent several years in the Canadian medical products industry in both medical products distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. He received his Bachelor of Arts degree in Commerce from Concordia University and graduate diploma in accountancy from McGill University, and his Masters of Business Administration from Duke University. He is a Certified Public Accountant in the state of Illinois and a Chartered Accountant in Ontario, Canada. Mr. Lapointe also serves on the Board of Directors of the Pharmaceuticals Research and Manufacturers of America (PhRMA), SciClone Pharmaceuticals, Inc. and Soligenix, Inc. and is a member of the Corporate Council of the National Organization for Rare Diseases (NORD).
Farrell, Stephen Stephen C. Farrell joined the Questcor Pharmaceuticals, Inc.’s Board of Directors in November 2007. Mr. Farrell served as President of PolyMedica Corporation until PolyMedica was acquired by Medco Health Solutions. During his eight year tenure at PolyMedica, Mr. Farrell served in various positions, including President, Chief Operating Officer, Chief Financial Officer, Chief Compliance Officer, and Treasurer. Earlier in his career, Mr. Farrell served as Senior Manager at PricewaterhouseCoopers LLP. Mr. Farrell holds an A.B. from Harvard University, and an M.B.A. from the University of Virginia. Mr. Farrell is also a certified public accountant
Silverman, Louis Louis E. Silverman has been appointed as Director of Questcor Pharmaceuticals, Inc. Mr. Silverman is currently Chief Executive Officer of privately-held Marina Medical Billing Service Inc. based in Cerritos, CA, a company focused on providing revenue cycle management services to emergency room physicians nationally. Prior to joining Marina Medical in August of this year, Mr. Silverman was President and Chief Executive Officer of LifeComm, Inc., a Qualcomm Incorporated incubated wireless health services start-up. Prior to Lifecomm. Mr. Silverman had a eight-year tenure as President and Chief Executive Officer of Quality Systems Inc (Nasdaq:QSII), where he led the developer of medical and dental practice management software. Previously, Mr. Silverman was the Chief Operations Officer of Corvel Corporation. He earned a Bachelor of Arts degree from Amherst College and a Masters in Business Administration from Harvard Graduate School of Business Administration.

Basic Compensation

Name Fiscal Year Total
Thompson, Virgil --
Bailey, Don 1,380,250
Sawka, Gary 147,397
Cartt, Stephen 852,298
Medeiros, David 639,811
Halladay, Steven 401,881
Young, David --
Zielonka, Jason --
Bradsher, Neal --
Lapointe, Gregg --
Farrell, Stephen --
Silverman, Louis --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Thompson, Virgil 0 0
Bailey, Don 341,661 2,787,300
Sawka, Gary 0 0
Cartt, Stephen 900,000 2,090,960
Medeiros, David 405,000 87,391
Halladay, Steven 260,416 2,030,930
Young, David 0 0
Zielonka, Jason 0 0
Bradsher, Neal 0 0
Lapointe, Gregg 0 0
Farrell, Stephen 0 0
Silverman, Louis 0 0

Insider Trading

Name Shares Traded Price
THOMPSON VIRGIL D 10,000 $2.28
THOMPSON VIRGIL D 10,000 $1.06
FARRELL STEPHEN C 30,000 $3.50
MEDEIROS DAVID JEFFREY 7,500 $6.47
MEDEIROS DAVID JEFFREY 25,000 $6.44
MEDEIROS DAVID JEFFREY 2,000 $6.47
MEDEIROS DAVID JEFFREY 2,600 $6.48
MEDEIROS DAVID JEFFREY 15,000 $6.42
MEDEIROS DAVID JEFFREY 11,500 $6.46
MEDEIROS DAVID JEFFREY 1,400 $6.48
MEDEIROS DAVID JEFFREY 50,000 $6.43
MEDEIROS DAVID JEFFREY 29,900 $6.13
CARTT STEPHEN LAHUE 100,000 $0.46
MEDEIROS DAVID JEFFREY 30,000 $6.17
MEDEIROS DAVID JEFFREY 28,000 $6.10
MEDEIROS DAVID JEFFREY 3,400 $6.25
MEDEIROS DAVID JEFFREY 10,400 $6.14
MEDEIROS DAVID JEFFREY 30,000 $6.20
MEDEIROS DAVID JEFFREY 1,700 $6.12
CARTT STEPHEN LAHUE 100,000 $6.12
MEDEIROS DAVID JEFFREY 30,000 $6.14
MEDEIROS DAVID JEFFREY 600 $6.26
MEDEIROS DAVID JEFFREY 21,000 $6.24
CARTT STEPHEN LAHUE 150,000 $0.46
CARTT STEPHEN LAHUE 25,000 $6.04
» Full list on Insider Trading
view people for: